Fintech

Vivatides Therapeutics Announces Oversubscribed $54 Million Series A Financing to Accelerate Extrahepatic RNA Therapeutics Development

Prnewswire·April 10, 2026 at 12:00 PM

/PRNewswire/ -- Vivatides Therapeutics, a global biotechnology company focused on developing extrahepatic RNA-targeting therapeutics, announced the successful...

Original Source

Prnewswire — www.prnewswire.com

Related in Fintech

CFTC Names Task Force for AI Rules
PYMNTS
Walmart Marketplace Drives General Merchandise Growth
PYMNTS
Fed finds stablecoins idle, confirms usage gap
PYMNTS
Judge blocks Arizona criminal charges against Kalshi
CoinDesk

Vivatides Therapeutics Announces Oversubscribed $54 Million Series A Financing to Accelerate Extrahepatic RNA Therapeutics Development

CFTC Names Task Force for AI Rules

Walmart Marketplace Drives General Merchandise Growth

Fed finds stablecoins idle, confirms usage gap

Judge blocks Arizona criminal charges against Kalshi